Artificial Intelligence (AI) and Generative AI (Gen AI) technologies have rapidly transformed various industries, including aerospace and space exploration. Stoke Space Technologies, a pioneering aerospace startup aiming to deliver fully reusable rockets, is leveraging AI and Gen AI to enhance operational efficiency, optimize rocket design, and advance overall mission success. This article explores Stoke Space's use of AI and Gen AI, details specific use cases and initiatives, examines broader industry trends and competitor activities, and discusses the anticipated impacts, challenges, and regulatory considerations surrounding AI adoption in the aerospace sector.

Relativity Space, now a leader in aerospace manufacturing and space exploration, represents a new wave of innovation in the rapidly evolving space industry. The company is widely recognized for its groundbreaking use of 3D printing to manufacture rockets, reducing production times and costs while increasing design flexibility. In recent years, Relativity Space has also embraced artificial intelligence (AI) and generative AI as transformative tools. These technologies allow the company to optimize manufacturing, design, and operations, keeping it at the forefront of a highly competitive industry.

Biogen Inc., a biotechnology pioneer focused on neuroscience, has embraced artificial intelligence (AI) and generative AI to accelerate drug discovery, optimize clinical trials, and enhance operational efficiency. As the pharmaceutical industry undergoes digital transformation, Biogen's AI initiatives represent a critical competitive advantage in addressing complex neurological diseases like Alzheimer's, multiple sclerosis, and ALS. This article examines Biogen's AI journey, industry trends, competitive landscape, and the regulatory environment shaping AI adoption in biopharmaceuticals.

The escalating complexity and financial burden of pharmaceutical research and development (R&D) have driven companies to explore transformative technologies to streamline processes and improve outcomes. Artificial Intelligence (AI) and its advanced subset, Generative AI (Gen AI), have emerged as pivotal tools in pharmaceutical and biotechnology. These technologies provide unprecedented capabilities in data analysis, predictive modeling, and process automation, enabling organizations to tackle long-standing drug discovery, manufacturing, and personalized medicine challenges. Roche and Genentech, pioneers in the pharmaceutical and biotechnology industries, have strategically integrated AI and Gen AI into their operations, leading the industry in innovation and efficiency.

ArcelorMittal, leader mondial de l'acier, s'engage résolument dans la transformation numérique de ses opérations avec l'intelligence artificielle comme pilier central de sa stratégie d'innovation. Cet article analyse les initiatives IA du groupe, les cas d'usage concrets, les tendances sectorielles, ainsi que les défis réglementaires et concurrentiels.

Artificial Intelligence (AI) and Generative AI (Gen AI) are rapidly reshaping industries globally, with healthcare and pharmaceuticals among the most profoundly transformed sectors. Novartis, a leading global pharmaceutical company, has emerged as a frontrunner in harnessing AI capabilities to drive innovation, enhance operational efficiency, and revolutionize patient care. This article explores Novartis’s AI and Gen AI initiatives, industry trends, competitor strategies, anticipated impacts, inherent risks, challenges, and the evolving regulatory landscape.

Eli Lilly and Company, a global pharmaceutical leader, has embraced artificial intelligence (AI) and generative AI (Gen AI) to modernize drug discovery and development, streamline manufacturing, and enhance patient-centric solutions. This article explores Eli Lilly's AI initiatives, broader industry trends, competitor strategies, anticipated impacts, and the associated risks, challenges, and regulatory frameworks shaping AI implementation in the pharmaceutical sector.

Pfizer, a global leader in biopharmaceutical innovation, is leveraging artificial intelligence (AI) and generative AI to reimagine how drugs are discovered, developed, and delivered. With increasing pressure on the pharmaceutical industry to accelerate innovation and reduce costs, Pfizer's strategic adoption of AI is positioning the company at the forefront of technological transformation.

The pharmaceutical industry is experiencing a profound transformation through artificial intelligence and generative AI technologies. AstraZeneca, one of the world's leading biopharmaceutical companies, has positioned itself at the forefront of this revolution, leveraging AI to accelerate drug discovery, optimize clinical trials, and enhance patient outcomes. This article explores AstraZeneca's AI journey, industry trends, competitive landscape, expected impacts, and the complex challenges facing AI adoption in pharmaceuticals.

Merck & Co., a global leader in pharmaceuticals and healthcare, has embraced artificial intelligence (AI) and generative AI (Gen AI) to drive innovation, improve efficiency, and develop new therapies. As the healthcare and pharmaceutical industries evolve, AI is pivotal in transforming drug discovery, manufacturing, patient care, and operational processes. This article delves into Merck's AI initiatives, industry trends, competitor strategies, the expected impact of AI, and the associated challenges and regulatory landscape

We are closing our series of posts AI in Pharma with the profile of Merck. It’s been a pleasure to dive into the industry and see how things are changing. Pharmaceutical companies are embracing AI fully, acquiring companies, signing partnerships, discovering new drugs in record time, reinventing their relationship with their customers, and facing an ever-changing regulatory environment.This Serie has been a success and I thank you all readers, and commenters for your support. Much appreciated! Melvine

Artificial Intelligence (AI) and its rapidly evolving branch, Generative AI, are reshaping industries worldwide, from healthcare to finance, manufacturing to entertainment, and beyond. The Blackstone Group has steadily leveraged AI in private equity and alternative investments to strengthen its operations, improve decision-making, and derive new value from its portfolio companies. This article explores how Blackstone is adopting and innovating around AI, especially Generative AI—details specific use cases, reviews broader industry trends and competitor activities, and discusses the expected impacts, associated risks, and regulatory environment around this transformative technology.

One of the world’s largest alternative investment managers, Apollo Global Management, embraces artificial intelligence (AI) and generative AI (GenAI) to enhance its operational capabilities, investment decision-making, and portfolio company performance. As AI continues to reshape the financial services landscape, Apollo’s adoption of these technologies aligns it with peers like Blackstone, KKR, and Carlyle, all racing to capitalize on the transformative potential of intelligent systems. This article explores Apollo’s AI and GenAI initiatives, key use cases, broader industry trends, competitive responses, and the associated risks and regulatory dynamics.

KKR & Co. Inc., one of the world’s leading global investment firms, has increasingly turned to artificial intelligence (AI) and generative AI (GenAI) as key enablers for value creation, operational efficiency, and investment decision-making. From portfolio company optimization to risk management and investor engagement, AI is not just a back-office experiment at KKR—it is becoming central to how the firm envisions the future of private equity.

Carlyle, a leading global investment firm with over $350 billion in assets under management, is at the forefront of integrating artificial intelligence (AI) and generative AI (Gen AI) into its operations and investment strategies. This note explores Carlyle's AI initiatives, use cases, industry trends, competitors' approaches, expected impacts, risks, challenges, and the regulatory environment, providing a detailed analysis for stakeholders in the financial sector.

This week, I had the incredible opportunity to attend a presentation by the Obvious Collective, a group of French artists and scientists based in Paris. The Sorbonne alumni club of New York organized the event. The collective presented its approach to visual art using AI. They started more than a decade ago and already have incredible success with their creations. You may remember their portrait of Mr Belamy, an AI-created portrait of an English lord, sold for half a million dollars at Christie’s.

Le groupe ENGIE, acteur majeur de la transition énergétique mondiale, intègre de plus en plus l'intelligence artificielle (IA) et ses applications génératives dans sa stratégie de transformation numérique. Face aux enjeux contemporains de décarbonation, d'efficacité énergétique et d'optimisation des réseaux, l'entreprise déploie ces technologies pour renforcer sa compétitivité et accélérer sa transition vers un modèle plus durable. Cet article explore l'écosystème d'IA chez ENGIE, ses applications concrètes, et le contexte plus large de l'utilisation de ces technologies dans le secteur énergétique.

As private equity enters a new digital age, few firms are embracing artificial intelligence (AI) and generative AI (Gen AI) with as much strategic clarity as CVC Capital Partners. With €200 billion in assets under management and over 140 portfolio companies worldwide, CVC is turning AI into a core lever of operational value creation, not just a buzzword.

Vista Equity Partners, a leading private equity firm with over $100 billion in assets under management as of September 2024, has integrated AI and generative AI into its strategy, focusing on software, data, and technology-enabled businesses. Their initiatives include the Vista Hackathon, which pilots generative AI-powered enterprise software solutions, and over 200 engagements in 2024 by their Value Creation Team to implement AI best practices in areas like talent development and contracting. They also host over 50 annual knowledge-sharing events to amplify AI capabilities across their portfolio.